Serveur d'exploration sur le peuplier

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD).

Identifieur interne : 003335 ( Main/Exploration ); précédent : 003334; suivant : 003336

Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD).

Auteurs : Sarah E. Hetrick [Australie] ; Rosemary Purcell ; Belinda Garner ; Ruth Parslow

Source :

RBID : pubmed:20614457

Descripteurs français

English descriptors

Abstract

BACKGROUND

PTSD is an anxiety disorder related to exposure to a severe psychological trauma. Symptoms include re-experiencing the event, avoidance and arousal as well as distress and impairment resulting from these symptoms.Guidelines suggest a combination of both psychological therapy and pharmacotherapy may enhance treatment response, especially in those with more severe PTSD or in those who have not responded to either intervention alone.

OBJECTIVES

To assess whether the combination of psychological therapy and pharmacotherapy provides a more efficacious treatment for PTSD than either of these interventions delivered separately.

SEARCH STRATEGY

Searches were conducted on the trial registers kept by the CCDAN group (CCDANCTR-Studies and CCDANCTR-References) to June 2010. The reference sections of included studies and several conference abstracts were also scanned.

SELECTION CRITERIA

Patients of any age or gender, with chronic or recent onset PTSD arising from any type of event relevant to the diagnostic criteria were included. A combination of any psychological therapy and pharmacotherapy was included and compared to wait list, placebo, standard treatment or either intervention alone. The primary outcome was change in total PTSD symptom severity. Other outcomes included changes in functioning, depression and anxiety symptoms, suicide attempts, substance use, withdrawal and cost.

DATA COLLECTION AND ANALYSIS

Two or three review authors independently selected trials, assessed their 'risk of bias' and extracted trial and outcome data. We used a fixed-effect model for meta-analysis. The relative risk was used to summarise dichotomous outcomes and the mean difference and standardised mean difference were used to summarise continuous measures.

MAIN RESULTS

Four trials were eligible for inclusion, one of these trials (n =24) was on children and adolescents. All used an SSRI and prolonged exposure or a cognitive behavioural intervention. Two trials compared combination treatment with pharmacological treatment and two compared combination treatment with psychological treatment. Only two trials reported a total PTSD symptom score and these data could not be combined. There was no strong evidence to show if there were differences between the group receiving combined interventions compared to the group receiving psychological therapy (mean difference 2.44, 95% CI -2.87, 7.35 one study, n=65) or pharmacotherapy (mean difference -4.70, 95% CI -10.84 to 1.44; one study, n = 25). Trialists reported no significant differences between combination and single intervention groups in the other two studies. There were very little data reported for other outcomes, and in no case were significant differences reported.

AUTHORS' CONCLUSIONS

There is not enough evidence available to support or refute the effectiveness of combined psychological therapy and pharmacotherapy compared to either of these interventions alone. Further large randomised controlled trials are urgently required.


DOI: 10.1002/14651858.CD007316.pub2
PubMed: 20614457


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD).</title>
<author>
<name sortKey="Hetrick, Sarah E" sort="Hetrick, Sarah E" uniqKey="Hetrick S" first="Sarah E" last="Hetrick">Sarah E. Hetrick</name>
<affiliation wicri:level="4">
<nlm:affiliation>Centre of Excellence in Youth Mental Health, Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10, 35 Poplar Road, Parkville, Melbourne, Victoria, Australia, 3054.</nlm:affiliation>
<orgName type="university">Université de Melbourne</orgName>
<country>Australie</country>
<placeName>
<settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Purcell, Rosemary" sort="Purcell, Rosemary" uniqKey="Purcell R" first="Rosemary" last="Purcell">Rosemary Purcell</name>
</author>
<author>
<name sortKey="Garner, Belinda" sort="Garner, Belinda" uniqKey="Garner B" first="Belinda" last="Garner">Belinda Garner</name>
</author>
<author>
<name sortKey="Parslow, Ruth" sort="Parslow, Ruth" uniqKey="Parslow R" first="Ruth" last="Parslow">Ruth Parslow</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20614457</idno>
<idno type="pmid">20614457</idno>
<idno type="doi">10.1002/14651858.CD007316.pub2</idno>
<idno type="wicri:Area/Main/Corpus">003135</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">003135</idno>
<idno type="wicri:Area/Main/Curation">003135</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">003135</idno>
<idno type="wicri:Area/Main/Exploration">003135</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD).</title>
<author>
<name sortKey="Hetrick, Sarah E" sort="Hetrick, Sarah E" uniqKey="Hetrick S" first="Sarah E" last="Hetrick">Sarah E. Hetrick</name>
<affiliation wicri:level="4">
<nlm:affiliation>Centre of Excellence in Youth Mental Health, Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10, 35 Poplar Road, Parkville, Melbourne, Victoria, Australia, 3054.</nlm:affiliation>
<orgName type="university">Université de Melbourne</orgName>
<country>Australie</country>
<placeName>
<settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Purcell, Rosemary" sort="Purcell, Rosemary" uniqKey="Purcell R" first="Rosemary" last="Purcell">Rosemary Purcell</name>
</author>
<author>
<name sortKey="Garner, Belinda" sort="Garner, Belinda" uniqKey="Garner B" first="Belinda" last="Garner">Belinda Garner</name>
</author>
<author>
<name sortKey="Parslow, Ruth" sort="Parslow, Ruth" uniqKey="Parslow R" first="Ruth" last="Parslow">Ruth Parslow</name>
</author>
</analytic>
<series>
<title level="j">The Cochrane database of systematic reviews</title>
<idno type="eISSN">1469-493X</idno>
<imprint>
<date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Child (MeSH)</term>
<term>Child Abuse, Sexual (psychology)</term>
<term>Clonazepam (therapeutic use)</term>
<term>Cognitive Behavioral Therapy (methods)</term>
<term>Combined Modality Therapy (methods)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Male (MeSH)</term>
<term>Paroxetine (therapeutic use)</term>
<term>Randomized Controlled Trials as Topic (MeSH)</term>
<term>Refugees (psychology)</term>
<term>Serotonin Uptake Inhibitors (therapeutic use)</term>
<term>Sertraline (therapeutic use)</term>
<term>Stress Disorders, Post-Traumatic (drug therapy)</term>
<term>Stress Disorders, Post-Traumatic (therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Association thérapeutique (méthodes)</term>
<term>Clonazépam (usage thérapeutique)</term>
<term>Enfant (MeSH)</term>
<term>Essais contrôlés randomisés comme sujet (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Inhibiteurs de la capture de la sérotonine (usage thérapeutique)</term>
<term>Mâle (MeSH)</term>
<term>Paroxétine (usage thérapeutique)</term>
<term>Réfugiés (psychologie)</term>
<term>Sertraline (usage thérapeutique)</term>
<term>Thérapie cognitive (méthodes)</term>
<term>Troubles de stress post-traumatique (thérapie)</term>
<term>Troubles de stress post-traumatique (traitement médicamenteux)</term>
<term>Violence sexuelle chez l'enfant (psychologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Clonazepam</term>
<term>Paroxetine</term>
<term>Serotonin Uptake Inhibitors</term>
<term>Sertraline</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Stress Disorders, Post-Traumatic</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Cognitive Behavioral Therapy</term>
<term>Combined Modality Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr">
<term>Association thérapeutique</term>
<term>Thérapie cognitive</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr">
<term>Réfugiés</term>
<term>Violence sexuelle chez l'enfant</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en">
<term>Child Abuse, Sexual</term>
<term>Refugees</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Stress Disorders, Post-Traumatic</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr">
<term>Troubles de stress post-traumatique</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Troubles de stress post-traumatique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Clonazépam</term>
<term>Inhibiteurs de la capture de la sérotonine</term>
<term>Paroxétine</term>
<term>Sertraline</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Child</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adolescent</term>
<term>Adulte</term>
<term>Enfant</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>
<b>BACKGROUND</b>
</p>
<p>PTSD is an anxiety disorder related to exposure to a severe psychological trauma. Symptoms include re-experiencing the event, avoidance and arousal as well as distress and impairment resulting from these symptoms.Guidelines suggest a combination of both psychological therapy and pharmacotherapy may enhance treatment response, especially in those with more severe PTSD or in those who have not responded to either intervention alone.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>OBJECTIVES</b>
</p>
<p>To assess whether the combination of psychological therapy and pharmacotherapy provides a more efficacious treatment for PTSD than either of these interventions delivered separately.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>SEARCH STRATEGY</b>
</p>
<p>Searches were conducted on the trial registers kept by the CCDAN group (CCDANCTR-Studies and CCDANCTR-References) to June 2010. The reference sections of included studies and several conference abstracts were also scanned.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>SELECTION CRITERIA</b>
</p>
<p>Patients of any age or gender, with chronic or recent onset PTSD arising from any type of event relevant to the diagnostic criteria were included. A combination of any psychological therapy and pharmacotherapy was included and compared to wait list, placebo, standard treatment or either intervention alone. The primary outcome was change in total PTSD symptom severity. Other outcomes included changes in functioning, depression and anxiety symptoms, suicide attempts, substance use, withdrawal and cost.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>DATA COLLECTION AND ANALYSIS</b>
</p>
<p>Two or three review authors independently selected trials, assessed their 'risk of bias' and extracted trial and outcome data. We used a fixed-effect model for meta-analysis. The relative risk was used to summarise dichotomous outcomes and the mean difference and standardised mean difference were used to summarise continuous measures.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>MAIN RESULTS</b>
</p>
<p>Four trials were eligible for inclusion, one of these trials (n =24) was on children and adolescents. All used an SSRI and prolonged exposure or a cognitive behavioural intervention. Two trials compared combination treatment with pharmacological treatment and two compared combination treatment with psychological treatment. Only two trials reported a total PTSD symptom score and these data could not be combined. There was no strong evidence to show if there were differences between the group receiving combined interventions compared to the group receiving psychological therapy (mean difference 2.44, 95% CI -2.87, 7.35 one study, n=65) or pharmacotherapy (mean difference -4.70, 95% CI -10.84 to 1.44; one study, n = 25). Trialists reported no significant differences between combination and single intervention groups in the other two studies. There were very little data reported for other outcomes, and in no case were significant differences reported.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>AUTHORS' CONCLUSIONS</b>
</p>
<p>There is not enough evidence available to support or refute the effectiveness of combined psychological therapy and pharmacotherapy compared to either of these interventions alone. Further large randomised controlled trials are urgently required.</p>
</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">20614457</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>08</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1469-493X</ISSN>
<JournalIssue CitedMedium="Internet">
<Issue>7</Issue>
<PubDate>
<Year>2010</Year>
<Month>Jul</Month>
<Day>07</Day>
</PubDate>
</JournalIssue>
<Title>The Cochrane database of systematic reviews</Title>
<ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD).</ArticleTitle>
<Pagination>
<MedlinePgn>CD007316</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD007316.pub2</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">PTSD is an anxiety disorder related to exposure to a severe psychological trauma. Symptoms include re-experiencing the event, avoidance and arousal as well as distress and impairment resulting from these symptoms.Guidelines suggest a combination of both psychological therapy and pharmacotherapy may enhance treatment response, especially in those with more severe PTSD or in those who have not responded to either intervention alone.</AbstractText>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess whether the combination of psychological therapy and pharmacotherapy provides a more efficacious treatment for PTSD than either of these interventions delivered separately.</AbstractText>
<AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">Searches were conducted on the trial registers kept by the CCDAN group (CCDANCTR-Studies and CCDANCTR-References) to June 2010. The reference sections of included studies and several conference abstracts were also scanned.</AbstractText>
<AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Patients of any age or gender, with chronic or recent onset PTSD arising from any type of event relevant to the diagnostic criteria were included. A combination of any psychological therapy and pharmacotherapy was included and compared to wait list, placebo, standard treatment or either intervention alone. The primary outcome was change in total PTSD symptom severity. Other outcomes included changes in functioning, depression and anxiety symptoms, suicide attempts, substance use, withdrawal and cost.</AbstractText>
<AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two or three review authors independently selected trials, assessed their 'risk of bias' and extracted trial and outcome data. We used a fixed-effect model for meta-analysis. The relative risk was used to summarise dichotomous outcomes and the mean difference and standardised mean difference were used to summarise continuous measures.</AbstractText>
<AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Four trials were eligible for inclusion, one of these trials (n =24) was on children and adolescents. All used an SSRI and prolonged exposure or a cognitive behavioural intervention. Two trials compared combination treatment with pharmacological treatment and two compared combination treatment with psychological treatment. Only two trials reported a total PTSD symptom score and these data could not be combined. There was no strong evidence to show if there were differences between the group receiving combined interventions compared to the group receiving psychological therapy (mean difference 2.44, 95% CI -2.87, 7.35 one study, n=65) or pharmacotherapy (mean difference -4.70, 95% CI -10.84 to 1.44; one study, n = 25). Trialists reported no significant differences between combination and single intervention groups in the other two studies. There were very little data reported for other outcomes, and in no case were significant differences reported.</AbstractText>
<AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">There is not enough evidence available to support or refute the effectiveness of combined psychological therapy and pharmacotherapy compared to either of these interventions alone. Further large randomised controlled trials are urgently required.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hetrick</LastName>
<ForeName>Sarah E</ForeName>
<Initials>SE</Initials>
<AffiliationInfo>
<Affiliation>Centre of Excellence in Youth Mental Health, Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10, 35 Poplar Road, Parkville, Melbourne, Victoria, Australia, 3054.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Purcell</LastName>
<ForeName>Rosemary</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Garner</LastName>
<ForeName>Belinda</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Parslow</LastName>
<ForeName>Ruth</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2010</Year>
<Month>07</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Cochrane Database Syst Rev</MedlineTA>
<NlmUniqueID>100909747</NlmUniqueID>
<ISSNLinking>1361-6137</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>41VRH5220H</RegistryNumber>
<NameOfSubstance UI="D017374">Paroxetine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5PE9FDE8GB</RegistryNumber>
<NameOfSubstance UI="D002998">Clonazepam</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>QUC7NX6WMB</RegistryNumber>
<NameOfSubstance UI="D020280">Sertraline</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002650" MajorTopicYN="N">Child Abuse, Sexual</DescriptorName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002998" MajorTopicYN="N">Clonazepam</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017374" MajorTopicYN="N">Paroxetine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012036" MajorTopicYN="N">Refugees</DescriptorName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020280" MajorTopicYN="N">Sertraline</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013313" MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>73</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2010</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>8</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">20614457</ArticleId>
<ArticleId IdType="doi">10.1002/14651858.CD007316.pub2</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Australie</li>
</country>
<region>
<li>Victoria (État)</li>
</region>
<settlement>
<li>Melbourne</li>
</settlement>
<orgName>
<li>Université de Melbourne</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Garner, Belinda" sort="Garner, Belinda" uniqKey="Garner B" first="Belinda" last="Garner">Belinda Garner</name>
<name sortKey="Parslow, Ruth" sort="Parslow, Ruth" uniqKey="Parslow R" first="Ruth" last="Parslow">Ruth Parslow</name>
<name sortKey="Purcell, Rosemary" sort="Purcell, Rosemary" uniqKey="Purcell R" first="Rosemary" last="Purcell">Rosemary Purcell</name>
</noCountry>
<country name="Australie">
<region name="Victoria (État)">
<name sortKey="Hetrick, Sarah E" sort="Hetrick, Sarah E" uniqKey="Hetrick S" first="Sarah E" last="Hetrick">Sarah E. Hetrick</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003335 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003335 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    PoplarV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:20614457
   |texte=   Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD).
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:20614457" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PoplarV1 

Wicri

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 12:07:19 2020. Site generation: Wed Nov 18 12:16:31 2020